YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

News Blast

July | August 2006

GE Healthcare and the Translational Genomics Research Institute (TGen) announced a strategic alliance designed to apply advanced cellular genomics technologies and strategies to improve and accelerate the discovery and development of new drugs. This research collaboration will support the mutual goals of translating basic genomic research into early health solutions for some of the most urgent problems facing healthcare today.

Acuity Pharmaceuticals’ lead clinical compound, bevasiranib sodium, formerly known as Cand5, appeared safe and showed clinical evidence of efficacy in the first results from the Phase ll C.A.R.E trial for the treatment of wet age-related macular degeneration. Bevasiranib is a first-in-class siRNA therapeutic designed to turn off or silence the gene that produces VEGF, the growth factor believed largely responsible for a leading cause of adult blindness.

The FDA approved a pill to treat HIV infection that combines three widely used antiretroviral drugs into one pill. The drug will be sold under the brand-name Atripla in the U.S. by Bristol-Myers Squibb and Gilead Sciences (with Merck involved outside the U.S.)

Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.